Clinical Trials on Laboratory Confirmed SARS-CoV-2 Infection Without Symptoms in Peru

Total 13 results

Universidad Peruana Cayetano Heredia

Completed

Hydroxychloroquine to Prevent SARS-CoV-2 Infection/COVID-19

SARS-CoV-2

Peru
Universidad Peruana Cayetano Heredia
Hospital Nacional Arzobispo Loayza

Terminated

Lactoferrin for Prevention of COVID-19 in Health Care Workers (LF-COVID)

SARS-CoV-2

Peru
CureVac
German Federal Ministry of Education and Research

Completed

A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19

Severe Acute Respiratory Syndrome | Covid19 | SARS-CoV-2 | Coronavirus

Panama, Peru
Universidad Peruana Cayetano Heredia
Barcelona Institute for Global Health

Completed

Randomized Phase IIA Clinical Trial to Evaluate the Efficacy of Ivermectin to Obtain Negative PCR Results in Patients With Early Phase COVID-19 (SAINT-PERU)

Coronavirus Infection | Covid19 | SARS-CoV Infection

Peru
Hospital Nacional Carlos Alberto Seguin Escobedo...

Completed

Tenofovir-DF Versus Hydroxychloroquine in the Treatment of Hospitalized Patients With COVID-19 (TEDHICOV) (TEDHICOV)

Covid19 | SARS-CoV Infection | Tenofovir

Peru
CureVac

Completed

A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older

Covid19 | SARS-CoV-2

Belgium, Spain, Germany, Argentina, Colombia, Dominican Republic, Mexico, Netherlands, Panama, Peru
HIV Vaccine Trials Network
National Institute of Allergy and Infectious Diseases (NIAID); HIV Prevention...

Completed

Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19

COVID-19 | SARS-CoV-2

United States, Zimbabwe, Malawi, Peru, South Africa, Zambia
COVID-19 Prevention Network
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

A Study of Immune Responses to the Virus That Causes COVID-19 (CoVPN 5001)

COVID-19 | SARS-CoV-2

United States, Malawi, Zimbabwe, Botswana, South Africa, Zambia, Argentina, Brazil, Mexico, Peru, Tanzania
AstraZeneca
Iqvia Pty Ltd

Completed

Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults

COVID-19 | SARS-CoV-2

United States, Chile, Peru
University of Minnesota
National Institute of Allergy and Infectious Diseases (NIAID); National Institutes...

Recruiting

Respiratory Virus Hospitalization Study (FLU 003 Plus)

Influenza | Novel Respiratory Virus-1 Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV) | Novel Respiratory Virus-2 Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)

United States, Australia, Spain, Denmark, Greece, Argentina, United Kingdom, Belgium, Chile, Germany, Peru, Thailand
Al-Azhar University
Helwan University; National Liver Institute, Egypt

Completed

Advanced Endoscopy During COVID-19

COVID-19 | Cholangiocarcinoma | SARS-CoV-2 | Pancreas Cancer | Obstructive Jaundice | Cholangitis, Secondary Biliary

Singapore, Germany, United States, Egypt, Peru
Hospital Nacional Edgardo Rebagliati Martins
Universidad de Piura

Completed

Postural Recruitment Maneuver in Patients With Acute Respiratory Distress Syndrome Due to COVID-19 Infection

ARDS | Sars-CoV2

Peru
Janssen Vaccines & Prevention B.V.

Completed

A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants (ENSEMBLE)

Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol

United States, Mexico, South Africa, Brazil, Chile, Colombia, Peru, Argentina

Clinical Trials on Laboratory Confirmed SARS-CoV-2 Infection Without Symptoms in Peru

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cameroon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations